CSL Seqirus published Phase 3 results for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc), showing superior immune response and safety in adults aged 50 and older. The vaccine combines three proven methods—MF59 adjuvant, cell-based production, and higher dose—to better protect older adults, whose immune systems weaken with age. The study of 7,699 participants across eight countries demonstrated the vaccine's superiority over existing options and persistent immunity throughout the flu season. Regulatory approvals are underway in multiple markets, with phased introductions expected, potentially improving flu prevention strategies for older adults globally.
KeyBanc initiated coverage on Air Products and Chemicals with a 'Sector Weight' rating, signaling expected performance in line with its sector. Despite the neutral outlook, the company showed strong profitability with a 110 basis point rise in adjust...
RH reported strong Q2 financial results, with earnings per share of $2.70 far exceeding analyst estimates of $0.38 and revenue of $922.20 million beating the $915.09 million forecast. This performance comes despite a recent 25% drop in RH's stock pri...
Tenon Medical's stock surged 116% after repaying $5.16 million in convertible debt, removing dilution risk for shareholders. Wealthfront also rose 15% following strong quarterly earnings that beat expectations. Digital Brands Group and PicoCELA saw s...
Kroger is set to release its earnings report on September 11, 2026, with analysts expecting earnings per share around $1.05-$1.06 and revenues near $34.64-$34.68 billion. Despite growth in digital sales and fresh product categories, the company faces...
On the day GameStop released its earnings report, an insider purchased $1 million worth of company shares. This move suggests strong confidence in the company's future despite market uncertainties. Insider buying often signals positive expectations a...
